On January 10, Cellectis S.A. (CLLS) shared that its licensed partner, Allogene Therapeutics Inc. has announced the removal of the FDA’s hold on its clinical
Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.